These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

1107 related articles for article (PubMed ID: 6991102)

  • 1. Randomized trial of chlorpromazine, caffeine, and methyl-CCNU in disseminated melanoma.
    Cohen MH; Schoenfeld D; Wolter J
    Cancer Treat Rep; 1980 Jan; 64(1):151-3. PubMed ID: 6991102
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Therapeutic potentiation of nitrosoureas using chlorpromazine and caffeine in the treatment of murine tumors.
    Rose WC; Trader MW; Dykes DJ; Laster WR; Schabel FM
    Cancer Treat Rep; 1978 Dec; 62(12):2085-93. PubMed ID: 751716
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combination chemotherapy for disseminated malignant melanoma with DTIC, vincristine, and methyl-CCNU.
    Einhorn LH; Furnas B
    Cancer Treat Rep; 1977 Aug; 61(5):881-3. PubMed ID: 329981
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Enhancement of semustine-induced cytotoxicity by chlorpromazine and caffeine in a human melanoma xenograft.
    Osieka R; Glatte P; Pannenbäcker R; Schmidt CG
    Cancer Treat Rep; 1986 Oct; 70(10):1167-71. PubMed ID: 3756939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Phase II study of vinblastine, methyl-CCNU, and medroxyprogesterone in advanced renal cell cancer.
    Hahn RG; Temkin NR; Savlov ED; Perlia C; Wampler GL; Horton J; Marsh J; Carbone PP
    Cancer Treat Rep; 1978 Jul; 62(7):1093-5. PubMed ID: 356971
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma.
    Creagan ET; Ahmann DL; Schutt AJ; Green SJ
    Cancer Treat Rep; 1982 Jun; 66(6):1425-6. PubMed ID: 7083244
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Chemosensitization by chlorpromazine (CPZ) and caffeine (C) in human melanoma xenografts sensitive or resistant to methyl-CCNU (semustine).
    Osieka R; Glatte P; Schmidt CG
    Strahlenther Onkol; 1989 Jul; 165(7):526-8. PubMed ID: 2749491
    [No Abstract]   [Full Text] [Related]  

  • 8. Effect of scheduling of combinations of 5-(3,3-dimethyl-1-triazeno)-imidazole-4-carboxamide and 1-(2-chloroethyl)-3-(4-methylcyclohexyl)-1-nitrosourea on the Harding-Passey and Cloudman S91 mouse melanomas.
    Hill HZ; Hill GJ
    Cancer Res; 1982 Mar; 42(3):838-42. PubMed ID: 7059982
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase II study of 5-fluorouracil, methyl-CCNU, and daunorubicin in colorectal cancer: a Cancer and Leukemia Group B study.
    White LA; Perry MC; Kardinal CG; Kennedy BJ; Weiss RB; Carey RW
    Cancer Treat Rep; 1979 Feb; 63(2):215-7. PubMed ID: 445497
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nitrosoureas in the management of disseminated malignant melanoma.
    Ahmann DL
    Cancer Treat Rep; 1976 Jun; 60(6):747-51. PubMed ID: 782696
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I trial of combination methotrexate and methyl-CCNU in patients with advanced neoplastic diseases.
    Lehane DE; Lane M; Tranum B; Costanzi J; Padilla F
    Cancer Treat Rep; 1977 Aug; 61(5):889-91. PubMed ID: 329982
    [No Abstract]   [Full Text] [Related]  

  • 12. Methyl-CCNU versus methyl-CCNU and 5-fluorouracil in carcinoma of the large bowel.
    Posey LE; Morgan LR
    Cancer Treat Rep; 1977 Nov; 61(8):1453-8. PubMed ID: 922750
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Immuno-chemotherapy in patients with disseminated metastasizing stage III melanoma. Randomized study with methyl-CCNU versus C. parvum plus methyl-CCNU].
    Kokoschka EM; Luger T; Micksche M
    Onkologie; 1978 Jun; 1(3):98-103. PubMed ID: 362293
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Methyl-CCNU in malignant melanoma--a divided dose schedule of administration.
    Wittes RE; Hong WK; Gatchell L; Krakoff IH; Golbey RB
    Oncology; 1977; 34(1):45-6. PubMed ID: 865760
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Phase II study of oral methyl-CCNU and prednisone in previously treated alkylating agent-resistant multiple myeloma.
    Tornyos K; Silberman H; Solomon A
    Cancer Treat Rep; 1977 Aug; 61(5):785-7. PubMed ID: 329977
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Multi-drug chemotherapy with and without radiation for carcinoma of the stomach and pancreas: a prospective randomized trial.
    Hazel JJ; Thirlwell MP; Huggins M; Maksymiuk A; MacFarlane JK
    J Can Assoc Radiol; 1981 Sep; 32(3):164-5. PubMed ID: 7028759
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Baker's antifol in combination with 5-fluorouracil and methyl-CCNU in the treatment of metastatic colorectal cancer: a Southwest Oncology Group Study (Protocol 7764).
    Shaw MT; Bonnet JD; Wilson H; Heilbrun LK
    Cancer Treat Rep; 1980; 64(2-3):247-50. PubMed ID: 7407758
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Results with methyl-CCNU and DTIC in metastatic melanoma.
    Costanza ME; Nathanson L; Schoenfeld D; Wolter J; Colsky J; Regelson W; Cunningham T; Sedransk N
    Cancer; 1977 Sep; 40(3):1010-5. PubMed ID: 332319
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Cisplatin, dacarbazine, and fotemustine plus interferon alpha in patients with advanced malignant melanoma. A multicenter phase II study of the Italian Cooperative Oncology Group.
    Daponte A; Ascierto PA; Gravina A; Melucci MT; Palmieri G; Comella P; Cellerino R; DeLena M; Marini G; Comella G;
    Cancer; 2000 Dec; 89(12):2630-6. PubMed ID: 11135225
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomized trial of chlorozotocin, neocarzinostatin, or methyl-CCNU in patients with malignant melanoma.
    Von Hoff DD; Amato DA; Kaufman JH; Falkson G; Cunningham TJ
    Am J Clin Oncol; 1984 Apr; 7(2):135-9. PubMed ID: 6230929
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 56.